Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

NANO-ENGINE A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

Coordinator
Universiteit Utrecht, Netherlands
Runs
1 April 2023 to 31 July 2026
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
7 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101098944

What the project is doing

In the project's own words, from its summary on CORDIS.

Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders. In this project, the consortium aims to assemble, characterize, and test the Targeted Nanoparticles, explore small-scale synthesis, conduct proof of concept studies and develop a preliminary business plan.

Unmet need: Currently, the accessibility of cell therapies, specifically CAR-T cell therapy, to the general patient population is limited by high costs, complexity, and safety concerns. These limitations are caused by: 1) ex vivo manufacturing processes of adoptive cell technologies, 2) requirement of highly specialized clinical facilities, and 3) the clinical toxicities and the need for preconditioning chemotherapy. Therefore, there is a large unmet need for alternative approaches that makes adoptive cell therapy truly affordable, scalable, and widely accessible in an out-patient setting.

Solution: We will develop Targeted Nanoparticles that form CAR-T cells in vivo, by combining a proprietary T cell binder-coated long-circulatory lipid nanoparticle and a non-viral, transposon-based, gene editing system. As such, we will circumvent the aforementioned issues associated with traditional cell therapies with reduced cost, complexity, and associated clinical risks, greatly increasing the accessibility of cell therapies to patients worldwide.

Consortium: The consortium will leverage main applicant NANOCELL’s deep knowledge on non-viral gene transfer technologies. UU provides critical expertise on nanomedicine, protein and cell engineering. KI/UOXF has developed a revolutionary single particle analysis method, which allows the consortium to obtain unique drug product characterization insights. SINTEF adds crucial know-how on bulk analysis of Targeted Nanoparticles, and is closely involved in regulatory standards for nucleic acid therapeutics.

QSAR uses machine learning to predict nanoparticle performance and minimize experimental work.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit UtrechtUtrechtNetherlandsCoordinator
Nanocell Therapeutics B.v.UtrechtNetherlandsParticipant
Sintef ASTrondheimNorwayParticipant
Qsar Lab Spolka Z Ograniczona OdpowiedzialnosciaGdanskPolandParticipant
Karolinska InstitutetStockholmSwedenParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI